Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based therapies for serious diseases.
Excellent balance sheet with moderate growth potential.
Share Price & News
How has Cantargia's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 7V3's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 7V3 exceeded the German Biotechs industry which returned 3.7% over the past year.
Return vs Market: 7V3 exceeded the German Market which returned 6.1% over the past year.
Price Volatility Vs. Market
How volatile is Cantargia's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Cantargia undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: 7V3 (€2.01) is trading above our estimate of fair value (€0.4)
Significantly Below Fair Value: 7V3 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 7V3 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 7V3 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 7V3's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 7V3 is overvalued based on its PB Ratio (9.2x) compared to the DE Biotechs industry average (3.2x).
How is Cantargia forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 7V3 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: 7V3 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 7V3's is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if 7V3's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if 7V3's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 7V3's Return on Equity is forecast to be low in 3 years time (19.7%).
How has Cantargia performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 7V3 is currently unprofitable.
Growing Profit Margin: 7V3 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 7V3 is unprofitable, and losses have increased over the past 5 years at a rate of -41.2% per year.
Accelerating Growth: Unable to compare 7V3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 7V3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 7V3 has a negative Return on Equity (-57.35%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Cantargia's financial position?
Financial Position Analysis
Short Term Liabilities: 7V3's short term assets (SEK213.8M) exceed its short term liabilities (SEK35.3M).
Long Term Liabilities: 7V3 has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 7V3 is debt free.
Reducing Debt: 7V3 has not had any debt for past 5 years.
Inventory Level: 7V3 has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 7V3's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 7V3 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 7V3 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Cantargia's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 7V3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 7V3's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 7V3's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 7V3's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 7V3's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Göran Forsberg (56yo)
Mr. Göran Forsberg has been the Chief Executive Officer at Cantargia AB since June 2014. Mr. Forsberg served as the Chief Business Officer of Active Biotech AB. He has more than 25 years' experience in bot ...
CEO Compensation Analysis
Compensation vs Market: Göran's total compensation ($USD321.81K) is below average for companies of similar size in the German market ($USD627.72K).
Compensation vs Earnings: Göran's compensation has increased whilst the company is unprofitable.
|Chief Executive Officer||5.7yrs||kr3.13m||0.10% SEK198.8k|
|Founder & Scientific Advisor||0yrs||no data||no data|
|0yrs||no data||no data|
|Chief Financial Officer||2.8yrs||no data||0.089% SEK172.0k|
|Vice President of Operations||6.1yrs||no data||0.028% SEK54.8k|
Experienced Management: 7V3's management team is seasoned and experienced (5.7 years average tenure).
|Chairman of the Board||4.1yrs||kr585.00k||0.049% SEK95.5k|
|Independent Director||7.1yrs||kr240.00k||no data|
|Independent Director||1.8yrs||kr329.00k||0.026% SEK50.9k|
|Founder & Director||10.1yrs||kr256.00k||0.53% SEK1.0m|
|Independent Director||4.1yrs||kr276.00k||no data|
|Independent Director||2.3yrs||kr343.00k||no data|
Experienced Board: 7V3's board of directors are considered experienced (4.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 7V3 insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.9%.
Cantargia AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Cantargia AB (publ)
- Ticker: 7V3
- Exchange: DB
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr2.043b
- Listing Market Cap: kr193.209m
- Shares outstanding: 91.01m
- Website: https://www.cantargia.com
Number of Employees
- Cantargia AB (publ)
- Scheelevägen 2
- Medicon Village
- Skåne County
- 223 81
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CANTA||OM (OMX Nordic Exchange Stockholm)||Yes||Share Capital||SE||SEK||Mar 2015|
|7V3||DB (Deutsche Boerse AG)||Yes||Share Capital||DE||EUR||Mar 2015|
|CANTAS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Share Capital||GB||SEK||Mar 2015|
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based therapies for serious diseases. It specializes in antibody-based treatment aimed at the molecular target Interleukin-1 Receptor Accessory Protein (IL1RAP), which has the potential to be used against various forms of cancer, as well as for autoimmune and inflammatory diseases. The company is developing CAN04, an antibody against IL1RAP to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system. It is also developing CANxx antibodies against IL1RAP for the treatment of autoimmune and inflammatory diseases. Cantargia AB (publ) has a collaboration agreement with BioWa. The company was founded in 2010 and is based in Lund, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/25 23:33|
|End of Day Share Price||2020/02/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.